Phase 1 trial of TSR-022 in combination with an anti-PD-1 antibody, TSR-042, in solid tumour patients
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2018
At a glance
- Drugs TSR 022 (Primary) ; TSR 042 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms AMBER
- 02 Aug 2018 According to a Tesaro media release, initial data from this trial has been submitted for inclusion in the Society for Immunotherapy of Cancer (SITC) annual meeting, November 2018, which includes results from lung cancer patients who have progressed on prior anti-PD-1 treatment.
- 03 May 2018 According to a TESARO Inc. media release, data from tumor-specific expansion cohorts are expected to be presented at a medical meeting later in 2018.
- 27 Feb 2018 According to a TESARO Inc. media release, this trial is enrolling three tumor specific cohorts and initial data is expected in 2H 2018.